Department of Gastroenterology, Ankara Ataturk Education and Research Hospital, Bilkent, Ankara, Turkey.
Saudi J Gastroenterol. 2014 Mar-Apr;20(2):113-9. doi: 10.4103/1319-3767.129476.
BACKGROUND/AIMS: There are a limited number of studies including the impact of antiplatelet drugs use on hospital outcomes for nonvariceal upper gastrointestinal bleeding. The aim of this study was to determine the effect of anti-aggregant, anti-coagulant and non-steroidal anti-inflammatory drugs upon hospital outcomes in patients with peptic ulcer bleeding.
The patients under treatment with antiaggregant, anticoagulant or non-steroidal anti-inflammatory drugs were categorized as exposed group (n = 118) and the patients who were not taking any of these drugs were categorized as non-exposed group (n = 81). We analyzed the data of drug intake, comorbid disease, blood transfusion, duration of hospital stay, Blatchford/total Rockall score and diagnosis of patients.
In total, 199 patients were included. Of these 59.3% (exposed group) were taking drugs. The patients in exposed group were significantly older than those in non-exposed group (62.9 ± 17.3 years; 55.5 ± 19.3 years, P = 0.005, respectively). Mean number of red blood cell units transfused (2.21 ± 1.51; 2.05 ± 1.87, P = 0.5), duration of hospital stay (3.46 ± 2.80 days; 3.20 ± 2.30 days, P = 0.532) and gastric ulcer rate (33% vs 23.4%, P = 0.172) were higher in exposed group than in non-exposed group but the differences were not statistically significant. Total Rockall and Blatchford scores of the patients were significantly higher in exposed group than in non-exposed group (3.46 ± 1.72 vs 2.94 ± 1.87, P = 0.045; 10.29 ± 3.15 vs 9.31 ± 3.40, P = 0.038).
Our study has shown that anticoagulants, antiaggregants and nonsteroidal anti-inflammatory drugs do not effect duration of hospital stay, red blood cell transfusion requirement and rebleeding for peptic ulcer bleeding.
背景/目的：目前仅有少数研究探讨抗血小板药物对非静脉曲张性上消化道出血患者住院结局的影响。本研究旨在明确抗栓药、抗凝药和非甾体类抗炎药对消化性溃疡出血患者住院结局的影响。
将使用抗血小板聚集药物、抗凝药物或非甾体类抗炎药物治疗的患者归入暴露组（n = 118），未使用上述药物的患者归入非暴露组（n = 81）。我们分析了药物摄入、合并症、输血、住院时间、Blatchford/总 Rockall 评分和患者诊断等数据。
共纳入 199 例患者，其中 59.3%（暴露组）正在服用药物。暴露组患者的年龄明显大于非暴露组（62.9 ± 17.3 岁；55.5 ± 19.3 岁，P = 0.005）。暴露组患者输注的红细胞单位数（2.21 ± 1.51；2.05 ± 1.87，P = 0.5）、住院时间（3.46 ± 2.80 天；3.20 ± 2.30 天，P = 0.532）和胃溃疡发生率（33% vs 23.4%，P = 0.172）均高于非暴露组，但差异无统计学意义。暴露组患者的总 Rockall 和 Blatchford 评分明显高于非暴露组（3.46 ± 1.72 vs 2.94 ± 1.87，P = 0.045；10.29 ± 3.15 vs 9.31 ± 3.40，P = 0.038）。
本研究表明，抗凝药、抗血小板聚集药物和非甾体类抗炎药对消化性溃疡出血患者的住院时间、红细胞输注需求和再出血无影响。
